Biogen Idec Submits Application In Europe For The Approval Of Fampridine-PR Tablets To Improve Walking Ability In People With Mu
Posted Jan 13 2010 12:00am
Biogen Idec (NASDAQ: BIIB) announced the submission of a marketing authorization application (MAA) to the European Medicines Agency for Fampridine Prolonged Release (Fampridine-PR) tablets, a novel oral therapy for the improvement of walking ability in adult patients with multiple sclerosis(MS). The company also has filed a New Drug Submission (NDS) to Health Canada. "Walking impairment has a significant impact on the lives of many people living with MS," said Alfred Sandrock, MD, PhD, Senior Vice President, Neurology Research and Development, Biogen Idec. "Fampridine-PR tablets may offer a novel approach to address this debilitating aspect of the disease by improving the walking ability of MS patients. We look forward to working with regulators to make this therapy available to people with MS in Europe and Canada."
. Keep Informed with News and Information regarding Multiple Sclerosis. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org . - Thank you . Have something to share with others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You ============================================